Defense World
08 Aug 2026, 07:34 UTC · 3w ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
Multiple research firms including Zacks, JonesTrading, and Wall Street Zen have downgraded Theravance Biopharma (TBPH) from 'Buy' or 'Strong-Buy' to 'Hold'. — A cluster of analyst downgrades typically signals a loss of conviction in the stock's near-term growth catalyst, reducing buying pressure.
-0.60Company insiders, including major shareholder Eli Samaha and SVP Rhonda Farnum, sold a combined 350,011 shares totaling over $6 million in the last three months. — Significant insider selling is often viewed as a bearish signal regarding the company's internal valuation or future outlook.
-0.40Dimensional Fund Advisors LP increased its holdings in TBPH by 14.5% in the first quarter. — Increased accumulation by a major institutional player provides some support for the stock price, though it is offset by the analyst downgrades.
+0.30Continue reading
6 related stories
Search tags
Institutional investors and hedge funds currently own 99.10% of the company's stock. — High institutional ownership indicates strong professional validation but also means the stock is highly susceptible to volatility if a few large funds exit.
+0.10Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
Zacks Investment Research
5d ago
